Abbott Laboratories Stock Drops 2 Percent on 13.78 Billion Shares Traded Ranking 73rd in Market Activity

On April 10, 2025, Abbott Laboratories (ABT) experienced a 2.00% decline in its stock price, with a trading volume of 13.78 billion, ranking 73rd in the day's market activity.

Abbott Laboratories is gearing up for its Q1 earnings report, with a particular focus on its medical devices segment. The company's Structural Heart, Rhythm Management, and Neuromodulation businesses are expected to play a significant role in the upcoming earnings report.

Abbott Laboratories has recently bolstered its leadership in heart failure management with the introduction of innovative technologies and solutions. The company's commitment to advancing heart failure treatments is evident in its ongoing research and development efforts.

Abbott Laboratories has received CE Mark approval for its Volt PFA System, which is designed to treat patients with abnormal heart rhythms, including atrial fibrillation. This approval allows Abbott to begin the rollout of the system in the European Union, further expanding its presence in the cardiac care market.